Cancer vaccines aim to stimulate the immune system to recognize and attack tumor-specific antigens, offering a promising strategy for OC, which expresses well-defined targets such as CA-125 (MUC16), NY-ESO-1, and WT1. This evidence concerns the gene MUC16 and neoplasm.